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Superoxide anion (O;-) production from human neutrophils timulated by N-formyl-L-methionyl-L-leucyl-L-phenylalanine (fMLP, 1 PM) was 
inhibited by preparations of the inhibitor of CAMP-dependent protein kinase, Rp-cyclic adenosine 3’,5’-phosphorothioate (Rp-CAMPS, 100 PM). 
This effect of Rp-CAMPS was reversed by xanthine amine congener (0.1 PM), an adenosine receptor antagonist, and by low concentrations of 
adenosine desaminase (0.02 mg/ml). HPLC analysis hows that these preparations of Rp-CAMPS contained concentrations of adenosine which could 
produce significant inhibition of fMLP-induced 0; production. These results suggest that Rp-CAMPS should be used with caution in cells or tissues 
containing adenosine receptors, and that preparations of Rp-CAMPS should be treated with adenosine desaminase before use to avoid activation 
of adenosine receptors. 
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1. INTRODUCTION 
Stimulation of receptors which activate adenylate 
cyclase potently inhibit the fMLP-stimulated 0’; pro- 
duction from neutrophils, presumably through produc- 
tion of CAMP and activation of CAMP-dependent pro- 
tein kinase (for review see [l]). An inhibitor of CAMP- 
dependent protein kinase would be expected to attenu- 
ate the effects of activators of adenylate cyclase, and to 
enhance the effect of fMLP on O;- production. 
Rp-CAMPS, a cell-permeable inhibitor of CAMP-de- 
pendent protein kinase, which reversibly binds to the 
CAMP binding site on the regulatory subunit of CAMP- 
dependent protein kinase (for review see [2]), has been 
widely used in experiments to investigate the role of the 
adenylate cyclase/cAMP pathway in receptor activity in 
intact cells (for example see [3-51, see also [2] and refer- 
ences therein). We wished to use Rp-CAMPS to investi- 
gate the role of CAMP in the inhibition of fMLP-in- 
duced 0; production in human neutrophils by isopre- 
naline. However, in our experiments, Rp-CAMPS by 
itself inhibited the fMLP-stimulated O;- production. We 
show here that this inhibition is due to adenosine pres- 
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ent in preparations of Rp-CAMPS, rather than Rp- 
CAMPS itself, activating adenosine receptors. These 
data indicates that Rp-CAMPS should be used with cau- 
tion in cell preparations containing adenosine receptors. 
2. MATERIALS AND METHODS 
Human neutrophils from young healthy male and female volunteers 
were isolated as previously described [6] and O;- production was mon- 
itored at 550 nm by continuous measurement of ferricytochrome re- 
duction, inhibitable by superoxide dismutase, as described in [7]. Test 
substances were added to cuvettes containing 1 x lo6 neutrophils in a 
total volume of 0.5 ml and the cuvettes were pre-incubated for 3 min 
at 37°C before the addition of fMLP to initiate O;- production. Analy- 
sis of Rp-cAMPS was performed with a L-6200 HPLC pump (Merck, 
Darmstadt, Germany) on a LiChrosphere RP-8 select B (Merck) re- 
verse-phase silica column (124 x 4 mm) using a fixed wavelength UV- 
detector (LDC, Riveiera Beach, CA) at 254 nm. In some experiments 
the peaks were analyzed with a diode array detector (Perkin-Elmer, 
tiberlingen, Germany). The eluent consisted of 2.5% acetonitrile and 
20 mM trimethyl ammonium formate buffer adjusted to pH 4.0; the 
elution rate was 1.5 ml/min. Injections of 20 ~1 were made from a 10 
mM stock solution of Rp-CAMPS. 
Q-CAMPS (lots 12,13, 15 and 17; BioLog, Bremen, Germany) was 
dissolved in deionized water to give a stock solution of 10 mM, ali- 
quoted and frozen at -2O’C except for one aliquot which was used 
immediately. Rp-CAMPS was kept on ice until addition to the reaction 
mixture. Enzymatic pretreatment of lots 15 and 17 was performed with 
adenosine desaminase (Sigma, Deisenhofen, Germany) and 2’,3’-3’,5’- 
cyclic nucleotide-dependent phosphodiesterases and alkaline phos- 
phatase (Sigma, Deisenhofen, Germany), respectively. XAC (RBI, 
Natick, MA) was initially dissolved in 0.1 mM acetic acid to give a 
stock solution of 5 mM and diluted subsequently in reaction buffer 
(composition given in [7]). DPCPX (RBI, Natick, MA) was initially 
dissolved in dimethyl sulphoxide to give a stock solution of 10 mM 
and subsequently diluted in deionized water. Adenosine and CAMP 
were obtained from Sigma (Deisenhofen, Germany) and were dis- 
solved in deionized water. 
Published by Elsevrer Science Publishers B V. 221 
Volume 318, number 3 FEBS LETTERS March 1993 
3. RESULTS AND DISCUSSION 
fMLP (1 PM) stimulated the formation of 6.01f0.33 
nmol 0’;/106 cells. Rp-CAMPS, at a concentration used 
in other intact cell experiments (100 PM) [2-51 unex- 
pectedly produced a profound inhibition of fMLP-stim- 
ulated O;- production (Figs. 1 and 2). This inhibitory 
effect was seen with solutions made from two separate 
batches of Rp-CAMPS (lots 12 and 13). We suspected 
that either Rp-CAMPS was acting as a weak adenosine 
receptor agonist, or that the Rp-CAMPS preparation 
contained adenosine. Adenosine has a marked inhib- 
itory effect on fMLP-stimulated 0’; production from 
human neutrophils (for review see [l], see also Figs. 1 
and 2) and is the starting material for synthesis of Rp- 
CAMPS. XAC, an A,/A,-adenosine receptor antagonist, 
and DPCPX, a relatively A,-selective adenosine recep- 
tor antagonist (for review see [S]), by themselves poten- 
tiated fMLP-stimulated O;- production, with XAC (0.1 
PM; 13.1 f 0.5 nmol 0’;/106 cells) being more potent 
than DPCPX (0.1 ,uM; 9.9 + 0.8 nmol 0’;/106 cells). The 
inhibitory effect of Rp-CAMPS (100 PM) was blocked 
by XAC (0.1 PM) and was unaffected by DPCPX at the 
same concentration. The inhibitory effect of adenosine 
(0.1 PM) was also substantially reduced by XAC and 
not blocked by DPCPX (Fig. 1). These results suggest 
that some component of the Rp-CAMPS preparation 
was activating A,-adenosine receptors. 
We then examined the effect of adenosine desaminase 
on the inhibitory effect of Q-CAMPS and other sub- 
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Fig. 1. The effect of adenosine receptor antagonists on the inhibition 
by &-CAMPS and adenosine of the fMLP-stimulated O;- production 
from human neutrophils. Test substances were added to the cells 3 min 
before addition of fMLP (1 PM). The results shown are the 
mean f S.D. of replicate observations (n = 2-3) on neutrophils from 
a single subject. Similar results were seen in two further experiments 
on neutrophils from different healthy volunteers. Results are shown 
as percent of the respective controls, absolute control values arc shown 
in section 3. 
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Fig. 2. The effect of adenosine desammase on the inhibition by isopre- 
naline (ISO), Rp-CAMPS, CAMP and adenosine (ADO) of the fMLP 
(1 PM) stimulated production of 0; from human neutrophils. Test 
substances and adenosine desaminase (ADA, 0.02 mg/ml) or vehicle 
were added to the cells 3 min before addition of fMLP. CON shows 
the effect of fMLP alone. The results shown are the mean f S.D. of 
replicate observations (n = 2-3) on neutrophils from a single experi- 
ment representative of at least three separate experiments on neutro- 
phils from different healthy volunteers. 
stances on fMLP-stimulated 0’; production. The inhib- 
itory effect of Rp-CAMPS was abolished by adenosine 
desaminase (0.02 mg/ml), and a small enhancement of 
fMLP-stimulated 0; production was seen (see Fig. 2). 
These results with this low concentration of adenosine 
desaminase are particularly significant, as Rp-CAMPS 
is resistant to degradation [2]. CAMP at a IO-times 
higher concentration than Rp-CAMPS (1 mM), pro- 
duced a smaller inhibition of fMLP-stimulated 0’; pro- 
duction (see Fig. 2), which was substantially reduced by 
adenosine desaminase. The inhibitory effect of 1 PM 
adenosine was reduced by this low concentration of 
adenosine desaminase (see Fig. 2) and the inhibitory 
effect of 0.1 PM adenosine was also substantially re- 
duced (data not shown). Isoprenaline (10 nM) inhibited 
fMLP-stimulated 0’; production to a similar extent as 
Rp-CAMPS (100 PM). This effect of isoprenaline was 
unaffected by adenosine desaminase, suggesting that 
adenosine desaminase was not acting non-specifically. 
Taken together, these results suggest hat the inhibition 
of fMLP-stimulated 0; production by RR-CAMPS, lots 
12 and 13, was due to the presence of adenosine or 
adenosine-like compounds, rather than an effect of Rp- 
CAMPS itself. 
HPLC analysis shows that the Rp-CAMPS prepara- 
tions lots 12 and 13 are over 99% pure. Fig. 3 shows the 
original trace from HPLC analysis of lot 13. In this 
preparation adenosine, identified by comparison with 
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Fig. 3. Original HPLC chromatogram of a sample of Q-CAMPS lot 13, showing relative absorbance at 254 nm. Retention times in min are shown 
above the peaks. Authentic adenosine is indicated by peak 1 which represents 0.05% of total material. Authentic Rp-CAMPS is indicated by peak 
5, which represents 99.7% of total material. Other peaks are unknown substances. Similar results were seen for lot 12. 
an authentic sample and by a corresponding UV spec- 
trum from a diode array detector, represents 0.05% of 
the material. However, even though the substance is of 
high purity, a cuvette with a final concentration of 100 
PM Rp-CAMPS would also contain about 0.05 PM ex- 
ogenous adenosine. This value is consistent with the 
data on inhibition of 0; production, which suggests 
that, if adenosine is the sole active agent, its concentra- 
tion is less than 0.1 PM, as XAC and adenosine desam- 
inase completely blocked the inhibitory effect of Rp- 
CAMPS preparations but only partially inhibited the 
effect of 0.1 PM adenosine. 
Our functional results cannot distinguish between 
adenosine and other by-products of Rp-CAMPS synthe- 
sis that are adenosine receptor agonists and substrates 
for adenosine desaminase. However, there appears to be 
sufficient authentic adenosine present to account for 
most of the inhibition of fMLP-stimulated 0; produc- 
tion. 
Regardless of whether adenosine is the sole active 
agent in these preparations, our results suggest that 
Rp-CAMPS should be used with caution in intact cells 
or tissues which contain adenosine receptors. Activa- 
tion of either adenosine A, receptors (mediating inhibi- 
tion of adenylate cyclase) or adenosine A, receptors 
(mediating activation of adenylate cyclase) could result 
in misinterpretation of experimental results. Although 
we have tested only the BioLog Rp-CAMPS here, the 
synthesis and purification method [2] suggests that most 
commercial preparations must contain some adenosine 
(or substances with adenosine receptor agonist activity). 
In addition another potential source for traces of ade- 
nosine must be taken into account. In spite of having 
sufficient stability for most applications in cell culture 
experiments, Rp-CAMPS slowly loses sulfur (0.1 %/week 
at 20°C and 0.2%/year at -20°C) [9] yielding CAMP 
which is metabolized via adenosine. CAMP release from 
Rp-CAMPS is drastically increased by strong oxidizing 
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agents. Among others hydrogen peroxide, ozone or 
oxiranes [lo] are able to convert phosphorothioates into 
corresponding cyclic phosphates. Presently there is no 
evidence that 0.i also accelerates degradation of Rp- 
CAMPS to CAMP, but it is reasonable to assume that 
it would. 
So, especially after prolonged storage in solution, 
there could be a risk of formation of some adenosine, 
provided that the necessary set of metabolic enzymes is 
present. For example, this could be the case when using 
cell culture media containing serum. 
In preliminary experiments, batches of Rp-CAMPS 
were enzymatically pretreated during the purification 
process. One batch (lot 15) was treated with adenosine 
desaminase and another batch (lot 17) was treated with 
cyclic nucleotide phosphodiesterases and alkaline phos- 
phatase, to degrade all potential adenosine-releasing 
nucleotide by-products, and finally with adenosine 
desaminase. Despite the disappearance of the adenosine 
peak from HPLC traces of both batches, Rp-CAMPS 
solutions from lot 1.5 inhibited fMLP-stimulated O;- for- 
mation to a similar extent as the Rp-CAMPS solutions 
from lots 12 and 13 (data not shown). Rp-CAMPS solu- 
tions from lot 17 produced a much smaller inhibition, 
which was reversed by XAC (data not shown). These 
results suggest that adenosine, or adenosine-like sub- 
stances, is produced during storage of purified Rp- 
CAMPS. Further experiments are presently underway to 
determine the best method of removal of contaminants 
from Rp-CAMPS preparations, to reduce degradation 
of Rp-CAMPS during storage and to determine the ef- 
fects of 0’; on cell-permeable cyclic nucleotides. 
We therefore recommend that at this time all experi- 
mental protocols should include either adenosine 
desaminase or an adenosine receptor blocker to avoid 
possible interference from activation of adenosine re- 
ceptors. 
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